Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892 · View on ClinicalTrials.gov ↗
Study Summary
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-2 inhibitor (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1RA). Participants will be followed for the occurrence of the trial primary endpoint of the total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality, counting all events from randomization until end of study.
Conditions Studied
Interventions
- DRUG SGLT2 inhibitor
- DRUG GLP-1 receptor agonist
Study Locations (8)
Maryland
- Johns Hopkins School of Medicine — Baltimore
Minnesota
- Essentia Health — Duluth
Missouri
- University of Missouri-Columbia — Columbia
New York
- Naomi Berrie Diabetes Center at New York Presbyterian-Columbia University — New York
North Carolina
- Duke University Hospital — Durham
South Carolina
- Medical University of South Carolina — Charleston
Tennessee
- Vanderbilt University Medical Center — Nashville
Wisconsin
- Medical College of Wisconsin — Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2022-09-26 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05390892
The ClinicalTrials.gov registry entry for NCT05390892 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 929 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with ASCVD appearing as the primary indexed condition, and to 2 interventions — of which SGLT2 inhibitor is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05390892 reports 8 study locations spanning 8 distinct geographic areas — top geographies include Maryland, Minnesota, Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05390892 about?
NCT05390892 is a clinical study titled "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes". PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or...
What is the current status of trial NCT05390892?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 6,000 participants. The study started on 2022-09-26. Estimated completion is 2029-03-01.
What conditions does trial NCT05390892 study?
This clinical trial studies the following conditions: ASCVD, Type2Diabetes. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05390892?
The interventions under investigation include: SGLT2 inhibitor (DRUG), GLP-1 receptor agonist (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05390892?
This trial is sponsored by Brigham and Women's Hospital, which has 929 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05390892 being conducted?
This trial has 8 study locations across Maryland, Minnesota, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.